LivaNova PLC (LIVN)
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Medical - Devices
LivaNova PLC
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 55.09M shares outstanding
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions.
The company operates through three key segments.
Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers.
The company's products are distributed globally through both its direct sales force and independent distributors.
Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Leadership
Vladimir Makatsaria
Chief Executive Officer & Director
Alex Shvartsburg
Chief Financial Officer
Natalia Sergeyevna Kozmina
Chief Human Resources Officer
Ahmet Tezel
Chief Innovation Officer
Employees
3K+
Country
GB
Sector
Healthcare
Website
livanova.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Chief Legal Officer | Grant/Award | 6.3K | -- | Sep 15, 2026 | |
| Director | Sale | 3.5K | $273.0K | Sep 10, 2026 | |
| Director | Sale | 2.3K | $187.3K | Sep 4, 2026 | |
| Director | Sale | 1.6K | $131.5K | Aug 31, 2026 | |
| Chief Innovation Officer | Option Exercise | 12.7K | -- | Aug 11, 2026 | |
| Chief Innovation Officer | Withholding/Transfer | 8.6K | $668.7K | Aug 11, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 7.6M | 13.7% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jul 2025 | 6.9M | 12.6% | 13G |
PRIMECAP MANAGEMENT CO/CA/ · also on 13F· may incl. warrants· filed Feb 2026 | 4.2M | 7.7% | 13G |
PRIMECAP MANAGEMENT CO/CA/ | 4.2M | 7.6% | 13F |
FMR LLC · also on 13F· joint filing· may incl. warrants· filed Sep 2026 | 3.2M | 5.8% | 13G |
FMR LLC | 3.1M | 5.7% | 13F |
Hood River Capital Management LLC | 2.6M | 4.7% | 13F |
Millennium Group Management LLC · also on 13F· joint filing· may incl. warrants· filed Apr 2026 | 2.4M | 4.4% | 13G |
AQR CAPITAL MANAGEMENT LLC | 2.4M | 4.3% | 13F |
Invesco Ltd. | 2.2M | 4.1% | 13F |
Insiders
- Liddy Anne M.Chief Legal Officer
- Bianchi FrancescoDirector
- Story BrookeDirector
- Tezel AhmetChief Innovation Officer
- Enxing Seng StacyDirector
- Barry James ChristopherDirector
- PODLOGAR SUSAN MDirector
- KOZY WILLIAM ADirector
- WILVER PETER MDirector
- SCHERMERHORN TODD CDirector
based on 55.09M shares outstanding
30d Avg
603.86K
60d Avg
624.65K
90d Avg
653.92K